Empowered by global genetic expertise

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

CentoPortal® – Online ordering portal

From ordering and sample submission through to receipt of the diagnostic report, CentoPortal® is designed to save time and reduce overall workload.

Login   or   Learn more about CentoPortal®

Please note that from June 1, 2017 diagnostic reports will be exclusively provided via CentoPortal®

Expertise you can trust

With CentoNIPT® we offer non-invasive prenatal testing that has the lowest test failure rate among all NIPT technologies on the market.

Request your free starter set now

Our Latest Scientific News

  • C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease

    Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceramides. Hallmark symptoms at clinical level are periarticular nodules, lipogranulomas, swollen and painful joints and a hoarse voice. FD phenotypes are heterogeneous varying from mild to very severe cases, with the patients not surviving past their first year of life. This study has the highest number of enrolled Farber patients and carriers reported to present. Liquid chromatography multiple reaction mass spectrometry (LC/MRM-MS) studies revealed that the ceramide C26:0 and especially its isoform 1 is a highly sensitive and specific biomarker for FD (p < 0.0001). The new biomarker can be determined directly in the dried blood spot extracts with low sample consumption. This allows for easy sample preparation, high reproducibility and use in high throughput screenings.

  • Increased regenerative capacity of the olfactory epithelium in Niemann–Pick disease type C1

    Niemann–Pick disease type C1 (NPC1) is a fatal neurovisceral lysosomal lipid storage disorder. The mutation of the NPC1 protein affects the homeostasis and transport of cholesterol and glycosphingolipids from late endosomes/lysosomes to the endoplasmic reticulum resulting in progressive neurodegeneration. Since olfactory impairment is one of the earliest symptoms in many neurodegenerative disorders, we focused on alterations of the olfactory epithelium in an NPC1 mouse model. Based on immunohistochemical evaluation of the olfactory epithelium, we analyzed the impact of neurodegeneration in the olfactory epithelium of NPC1-/- mice and observed considerable loss of mature olfactory receptor neurons as well as an increased number of proliferating and apoptotic cells.

  • AMPA-receptor specific biogenesis complexes control synaptic transmission and intellectual ability

    AMPA-type glutamate receptors (AMPARs), key elements in excitatory neurotransmission in the brain, are macromolecular complexes whose properties and cellular functions are determined by the co-assembled constituents of their proteome. Here we identify AMPAR complexes that transiently form in the endoplasmic reticulum (ER) and lack the core-subunits typical for AMPARs in the plasma membrane. Central components of these ER AMPARs are the proteome constituents FRRS1l (C9orf4) and CPT1c that specifically and cooperatively bind to the pore-forming GluA1-4 proteins of AMPARs. Our results provide insight into the early biogenesis of AMPARs and demonstrate its pronounced impact on synaptic transmission and brain function.


Dear Prof. Rolfs, ...

I want to thank you again for your support in our activity in rare disease field in Romania. It was a great meeting at Rare Disease Day symposium in Bucharest on 23th February. Centogene team participation contributed immensely to our event. It's amazing how much value you offered to our specialists looking to learn about rare diseases and new genomic technologies. Read more...

Romania, March 2017

Dear colleagues, ...

... the world's best laboratory Centogene!

Ukraine, December 2016

Congratulation ...

... for this success. The secret key of such achievement is the continuous unlimited help, collaboration, dedication and hard work from Centogene team. Special thanks to Daniel and Rami. Looking forward for more publications togother in the near future.

Riyadh, November 2016

I am an experienced neurogeneticist ...

and moved back to Lebanon from the US wanting to make a difference in the diagnosis, care and prevention of recurring neurogenetic disorders in the Lebanese. Alas, I was only partially successful, ... Read more

Lebanon, January 2016

Thank you ...

... very much for your unlimited help and support.

Saudi-Arabia, December 2015

Subscribe to our Newsletter

CENTOGENE is raising venture capital to strengthen its R&D activities and drive its global growth.

Read more

CENTOGENE has recently added the following single gene tests and Next Generation Sequencing panels to its portfolio. CENTOGENE‘s NGS panel composition always...

Read more

An agreement was recently signed for an exciting new collaboration between CENTOGENE, Germany and University Hospital St. Ivan Rilski Sofia, Bulgaria.

Read more

CENTOGENE is proud to announce today our Euro 25 million financing round led by TVM Capital Life Science in cooperation with DPE Deutsche Private Equity,...

Read more

CENTOGENE AG (CENTOGENE) has been working together for years with local, national, and international partners in developing biomarkers to be used in the early...

Read more

Another milestone is reached for our new headquarter in Rostock: Yesterday, we celebrated together with colleagues, friends and partners the Roofing Ceremony....

Read more

CENTOGENE has recently added numerous single gene tests and next generation sequencing (NGS) panels to its portfolio. Our NGS panel compositions always reflect...

Read more

The ‘Rare Disease Day’ is celebrated every February, to help raise awareness and build community for all those affected by rare genetic diseases.

Read more

Our new headquarter in Rostock, CentoNew, is growing rapidly – we started the countdown to our move-in November 2017.

The new headquarter in Rostock will...

Read more